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Abstract: Vogt–Koyanagi–Harada syndrome is a cause of noninfectious panuveitis, leading 
to significant vision loss in many patients. It is an autoimmune disease occurring in geneti-
cally susceptible individuals and clinically presents as bilateral panuveitis with serous retinal 
detachments and hyperemic, swollen optic discs, which are associated with neurological and 
auditory manifestations. Early diagnosis and prompt and adequate treatment with immuno-
suppressive agents (corticosteroids and other immunosuppressive drugs) may halt disease 
progression and prevent recurrences and vision loss. This review summarizes the current 
knowledge on the variable clinical aspects of this disease, highlighting diagnostic and treat-
ment strategies.
Keywords: multifocal choroiditis, serous retinal detachment, panuveitis, sunset glow fundus, 
starry sky, corticosteroid
Introduction
Vogt–Koyanagi–Harada disease (VKHD) is a sight-threatening disease and a 
common cause of noninfectious panuveitis.1,2 It is described as a multisystemic, 
granulomatous inflammation related to T-cell-mediated autoimmune dysregulation, 
targeting melanocytic self-antigens. The tyrosinase family proteins and gp100 are 
common antigenic targets for VKHD.1,3–5 The disease has a predilection for affect-
ing melanocyte-containing tissues in the eye, the central nervous system (CNS), the 
inner ear and the skin, appears in genetically susceptible individuals and is related to 
HLA-DRB1*0405.6–8 Patients usually present with bilateral panuveitis preceded by a 
mild prodromal illness, associated with neurological and auditory features. However, 
it is common for patients to present with isolated ocular involvement during the early 
phases of the disease, with the choroid being the main site of ocular inflammation 
together with potential involvement of the iris and ciliary body. During the early 
acute phase of the disease, the inflammation is characterized by non-necrotizing 
diffuse granulomas, which persist following recurrences (chronic recurrent phase). 
As the disease progresses, it undergoes a chronic convalescent phase, which is 
characterized by a non-granulomatous inflammation, with later involvement of the 
choriocapillaris in the chronic recurrent phase.9,10 The disease has a variable clinical 
presentation, and clinical diagnosis is aided by the help of ophthalmic imaging such 
as fundus fluorescein angiography (FFA), indocyanine green angiography (ICG), 
and optical coherence tomography (OCT). Novel diagnostic techniques, which can 
demonstrate choroidal structure and precise retinal function, are now employed to 
assist in early diagnosis, leading to prompt treatment and monitoring of ongoing 
ocular inflammation.
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Historical aspects and epidemiology
Ocular inflammation with poliosis was described in the 
first century AD by Ali-ibn-Isa.11 In 1906, Vogt12 reported a 
case of a 16-year-old patient with iridocyclitis and poliosis. 
In 1929, Yoshizo Koyanagi described 16 cases with similar 
features, including six new cases.13 In addition to the anterior 
uveitis and extraocular manifestations described by Vogt and 
Koyanagi, Harada14 described in 1926 a primarily posterior 
uveitis with exudative retinal detachments and pleocytosis of 
cerebrospinal fluid (CSF): an abnormal increase in the amount 
of lymphocytes and monocytes with normal glucose, as well 
as the prodromal phase of the disease and the integumentary 
signs. These findings were later noted by Babel, Bruno, and 
McPherson to represent a single, progressive syndrome, and 
the name was combined into VKHD syndrome.15
VKHD has variable incidence; it appears to be more preva-
lent in people with Asian, Hispanic, Indian, Native American, 
or Mediterranean origin, accounting for 7%–22.4% of uveitis 
referrals.16–21 It is uncommon in Caucasians and people 
of Turkish descent, where it accounts for ,3% of uveitis 
referrals.22–25 VKHD commonly affects young females26–28 
between 20 and 50 years of age,1 at a ratio of 2:1 in most 
large series.29 However, pediatric cases,30–32 elderly onset33 and 
equal sex predilection have been reported in some studies.34
Classification and clinical features
According to the revised diagnostic criteria proposed by 
the American Uveitis Society,35 in its complete form, 
VKHD is defined as a non-traumatic bilateral panuveitis 
and is associated with integumentary, neurological/auditory 
signs. Probable (ocular) VKHD is characterized as match-
ing ocular manifestations but in the absence of extraocular 
manifestations. Patients with the incomplete form of the 
disease usually present with bilateral ocular involvement 
with either integumentary features or neurologic/auditory 
manifestations.35 In all forms of the disease, there should 
be no history of ocular surgery and no clinical or laboratory 
evidence suggestive of other ocular diseases.35 It is important 
to recognize that although classically VKHD is a multisys-
temic disease, patients may fail to develop the complete or 
incomplete forms, and isolated ocular involvement has been 
reported in 45% of patients with acute VKHD and up to 58% 
of those presenting with chronic disease.36
VKHD is a multiphasic disease that classically has four 
clinical phases or stages with variable clinical features in 
different ethnic groups: 1) prodromal; 2) acute; 3) chronic 
convalescent; and 4) chronic recurrent stage.
The prodromal phase, which may mimic a viral infection, 
generally precedes the ocular inflammation by a few days 
and lasts for 1–2 weeks. Patients typically complain of CNS 
and auditory symptoms including headaches, neck stiffness, 
photophobia, fever, orbital pain, scalp or skin sensitivity, and 
focal neurological deficits such as cranial nerve palsies.1,28 
They may also have hearing loss, particularly for higher 
frequencies, dysacousia, vertigo, and tinnitus,1,37,38 with less 
frequent auditory features observed in Hispanic patients.39 
CSF samples from lumbar punctures show pleocytosis 
in .80% of cases,40,41 and brain imaging studies can occa-
sionally demonstrate focal parenchymal lesions.42
In the eye, the acute phase of VKHD is characterized by a 
panuveitis or posterior uveitis with multifocal serous retinal 
detachments (SRDs). Vitreous inflammation is commonly 
noted with a low-grade non-granulomatous anterior uveitis 
seen in some patients.10,34,41 The diffuse choroidal thicken-
ing seen on OCT scans during the acute phase of VKHD 
correlates with diffuse mononuclear inflammatory cellular 
infiltration of the uvea with sparing of the choriocapillaris9 
and the appearance of Dalen-Fuchs nodules on histopatho-
logical studies. The Dalen-Fuchs nodules are aggregates of 
lymphocytes and pigment-laden macrophages that appear 
mainly in the posterior pole between Bruch membrane and 
the retinal pigment epithelium (RPE).9,10 The inflammation 
lasts several weeks, and early treatment may prevent the later 
development of the chronic phases of the disease in up to 
a third of cases.26,43,44 However, progression to the chronic 
convalescence phase occurs in 28%–62% of patients who 
present with acute VKHD, possibly due to more severe and 
rapid disease onset.26,45
The chronic convalescence phase usually develops 
3–4 months after the onset of the disease and lasts from 
several weeks to years, during which time patients usually 
present with non-granulomatous panuveitis, poliosis of the 
eyebrows and eyelashes, vitiligo, and alopecia, as well as 
depigmentation of the choroid resulting in a bright-orange 
hue. The optic nerve remains pale, leading to the appearance 
of sunset glow fundus.1,2 This depigmentation of the integu-
mentary system usually follows ocular and CNS involvement 
in VKHD and is more commonly seen in Japanese than in 
Hispanic patients.1,39 Despite early high-dose corticosteroid 
treatment, progression to the chronic recurrent phase may 
occur in up to 79% of the total cases who presented with 
acute VKHD.44
During the chronic recurrent phase, patients present 
with recurrent granulomatous anterior uveitis (Figure 1), 
and choroidal thickening develops.46–48 Approximately 25% 
of VKHD patients develop posterior and anterior segment 
recurrences, mainly in cases of more aggressive disease with 
poor response to immunosuppressive treatment.27 Anterior 
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segment recurrences were found to be associated with 
choroidal inflammation and insufficient choroidal circulation 
demonstrated on ICG and OCT scans.48,49
Ocular findings in VKHD
In the eye, orbital pain, photosensitivity and tearing have 
been reported during the prodromal phase of VKHD.1 As the 
disease progresses to the acute phase, panuveitis manifests 
and patients commonly present with transient attacks of panu-
veitis or posterior uveitis with multifocal choroiditis lesions 
(Figure 2A), which progress to multifocal serous detachments 
and can coalesce into diffuse SRD (Figure 2B),41,50 resulting in 
reduced vision. SRD might initially be misdiagnosed as central 
serous chorioretinopathy (CSCR).51 However, in the absence 
of ocular inflammation and other systemic features of VKHD, 
the presence of optic disc hyperemia and disc leakage on FFA 
support the diagnosis of VKHD rather than CSCR.51
Although bilateral simultaneous involvement has been 
observed in the majority of patients, involvement of the 
second eye can take up to 2 weeks, with delayed involve-
ment reported to occur up to 6 years after the first eye.52 
Sporadic cases of uniocular disease have also been reported 
with a follow-up time of 16 years;32,53,54 therefore, uniocular 
presentation should not exclude the diagnosis or delay start-
ing treatment.
Unilateral and bilateral optic disc hyperemia (Figure 3) 
without visual field loss is a frequent presentation in acute 
VKHD55–57 and is the most common finding in acute VKHD 
patients with no SRD at presentation.58
Optic disc involvement in acute VKHD is found to be 
more common in females and patients with a mean age 
of 55 years, who also have a greater likelihood of vision 
loss or progression to the chronic phases.50 In addition to 
older age at presentation, optic disc swelling is found to 
correlate significantly with the morphology of the optic 
nerve (a smaller cup-to-disc ratio and a higher disc–macula 
distance to disc diameter).57 Swollen optic discs may be the 
only presenting sign and should be differentiated from other 
conditions,56 such as optic neuritis,59 diabetic papillopathy,58 
central retinal vein occlusion, or anterior ischemic optic neu-
ropathy (AION). Extensive optic disc swelling can itself lead 
to further optic nerve pathology, and patients can develop 
AION following the resolution of the optic disc swelling 
and SRD. This is thought to be due to an impaired posterior 
ciliary artery supply to the optic nerve, secondary to severe 
choroidal inflammation.60–62 Involvement of the optic nerve 
Figure 1 Color photograph of a patient in the chronic recurrent phase of the 
vKHD showing acute anterior uveitis and mild poliosis (white arrow).
Abbreviation: vKHD, vogt–Koyanagi–Harada disease.
Figure 2 Color retinal photographs of a patient during the acute phase of vKHD.
Notes: (A) Multifocal choroiditis lesions of variable size representing along the superior arcade (black arrow). (B) The posterior pole depicting a hyperemic optic disc (white 
arrow), multifocal choroiditis (black arrow), and multiple areas of SRDs (red arrows).
Abbreviations: vKHD, vogt–Koyanagi–Harada disease; SRDs, serous retinal detachments.
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leading to fixed dilated pupils has also been observed in a 
28-year-old patient with acute VKHD.63
Choroidal folds are ripples in the RPE, Bruch membrane 
and the inner aspect of the choroid and have been described 
to accompany or precede the development of SRD in up to 
71% of eyes with acute VKHD.64 These folds (Figure 3) 
can be detected on fundus examination and are more eas-
ily identifiable on FFA, ICG, and OCT scans.65–67 Their 
reappearance on OCT is predictive of recurrence of SRD.68 
In studies examining VKHD patients, choroidal folds were 
noted in between 12% and 57% of cases. Their occurrence 
was related with poor visual acuity at presentation, as well 
as poor visual outcome,65,66,69 disc swelling, and the develop-
ment of choroidal thinning and sunset glow fundus later in 
the course of the disease.69
Scleral involvement in patients in the acute phase of 
VKHD has been observed with case reports of patients 
presented with unilateral or bilateral posterior scleritis and 
choroidal thickening.70 Extraocular features of VKHD with 
bilateral posterior scleritis, bilateral SRD, and optic disc 
swelling were also observed.71
Rare presentations of acute VKHD include angle closure 
glaucoma, moderately elevated intraocular pressure (IOP) 
with variable degrees of intraocular inflammation72–74 or RPE 
tears that can be seen bilaterally without choroidal neovascu-
larization (CNV) and are thought to be due to acute choroidal 
inflammation.75 Vitreomacular traction (VMT) that rapidly 
progresses to full-thickness macular hole (MH) formation has 
also been noted to develop during acute VKHD,76 possibly 
due to active inflammation.
In eyes that progress to the chronic convalescence stage, 
resolution of SRDs with the development of chorioretinal 
depigmentation results in an orange-red discoloration of the 
fundus giving the distinct sunset glow fundal appearance 
(Figure 4) and perilimbal vitiligo (Sugiura’s sign), which 
suggest ongoing uveal inflammation. Sunset glow fundus 
has been reported to develop as soon as 4 months after the 
initial presentation, despite treatment with high-dose immu-
nosuppressive agents.10,45 Histological studies suggest that 
this is secondary to choroidal melanocyte loss from diffuse 
granulomatous choroiditis.10,77 The development of sunset 
glow fundus was found to be related to increased numbers of 
inflammatory cells in CSF samples and severe CNS involve-
ment at presentation.78
The convalescent phase is further characterized by the 
appearance of numerous small choroidal depigmented atro-
phic and hyperpigmented lesions in the retinal periphery 
(Figure 5)79 and peripapillary subretinal fibrosis lesions 
(Figure 4A), as well as the Dalen-Fuchs nodules that can be 
seen in all phases of the disease.9,10 Choroidal atrophy due to 
subfoveal loss of the choriocapillaris has been confirmed on 
spectral domain OCT (SD-OCT) scans and correlated with 
duration of the disease, lower visual acuity, and atrophy of 
overlying retina and RPE.80
Other uncommon findings in this phase of the disease 
include progressive scleral changes and posterior scleritis 
possibly due to ongoing chronic choroidal inflammation,81–83 
as well as VMT and epiretinal membranes (ERMs), possibly 
due to RPE migration later in the course of the disease.84
The chronic recurrent phase is characterized by episodes 
of granulomatous anterior uveitis with mutton fat keratic 
precipitates, iris nodules, and posterior synechiae.46 A pro-
spective study that examined 70 eyes with acute VKHD and 
92 eyes with recurrent disease, before and after treatment with 
Figure 3 Color retinal photographs of right (A) and left eye (B) showing swollen and hyperemic optic discs (white arrows), with choroidal folds disc (black arrows), in the 
acute phase of vKHD.
Abbreviation: vKHD, vogt–Koyanagi–Harada disease.
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immunosuppressive agents, showed a significantly higher 
anterior segment cell count and flare level in the eyes during 
the chronic recurrent phase, possibly reflecting a refractory 
inflammation with lasting breakdown of the blood–aqueous 
barrier.85 Peripheral iris stromal and pigment epithelium 
depigmentation may develop due to ciliary body inflamma-
tion, associated with the severe lasting anterior uveitis.86,87 RPE 
clumping and disruption seen as multiple foci of hypopigmen-
tation, in addition to sunset glow fundus and chorioretinal atro-
phy, are prominent findings on fundus examination. Though 
they do not appear to be active chorioretinal inflammation, 
OCT and ICG studies have demonstrated increased choroidal 
thickness during this stage, reflecting subclinical inflammation 
that may require additional immunosuppression.47,48
imaging in vKHD
Imaging plays a major role in the diagnosis of VKHD, 
monitoring of the intraocular inflammation and response to 
treatment, as well as the development of complications.
Fundus fluorescein angiography
FFA is used to aid in the diagnosis, during follow up,88,89 and 
as a prognostic tool in VKHD.90 (Figure 6A; color retinal 
photograph showing deep yellow lesions of variable size and 
multiple SRD). During the early venous phase of FFA, active 
inflammation in the acute phase leads to delayed choroidal 
perfusion in the posterior pole and retinal periphery, dis-
played as areas of hypofluorescent (Figure 6B).91 Numerous 
hyperfluorescent pinpoint foci of leakage, which coincide 
with areas of choroiditis, are manifested at the level of RPE 
(Figure 6C).91 This is accompanied by multilobular dye pool-
ing in the subretinal space, each lobule surrounded by a dark 
rim (Figure 6D) that is thought to be related to the formation 
of subretinal septa as demonstrated on previously published 
OCT scans.88,92,93 Homogeneous staining on FFA is usually 
seen in areas of retinal detachment and optic disc leakage.88,90 
A hot disc can be observed in up to 94.4% of patients with 
acute VKHD and 66.6% of those in the chronic convalescent 
phase (Figure 7).88 Numerous hyperfluorescent pinpoint foci 
of leakage at the level of RPE result in a classic “starry sky” 
appearance on the FFA that is highly suggestive of VKHD 
(Figure 8). Hypofluorescent lines corresponding to choroidal 
folds are also seen.65,91 In a series of 95 patients with VKHD, 
11 (12%) showed choroidal folds manifested as hypofluores-
cent bands radiating from the optic disc.65 During the chronic 
phases of VKHD, FFA usually shows RPE window defects, 
spotted hyper- and hypofluorescence and blockage of choroidal 
Figure 4 Color retinal photographs of right (A) and left eye (B) during the convalescent phase of vKHD, showing sunset glow fundus with pale optic discs (white arrows) 
and bright-orange choroids (black arrows). Note the peripapillary atrophy (gray arrow) and macular scaring (blue arrow) in (A).
Abbreviation: vKHD, vogt–Koyanagi–Harada disease.
Figure 5 Color retinal photograph displaying sunset glow fundus with a numerous 
small choroidal depigmented atrophic lesions (black arrow) and hyperpigmented lesions 
(white arrow) in the retinal periphery during the convalescent phase of vKHD.
Abbreviation: vKHD, vogt–Koyanagi–Harada disease.
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Figure 6 Color retinal and FFA photographs of a patient in the acute phase of vKHD showing (A) hyperemic optic disc with deep yellow lesions of variable size and multiple 
SRD, (B) early FFA showing delayed choroidal filling, (C) mid phase of FFA showing pinpoint hyperfluorescent leakage at the RPE level (D) with pooling of the dye in the 
subretinal space in the late phase of the angiogram.
Abbreviations: FFA, fundus fluorescein angiography; VKHD, Vogt–Koyanagi–Harada disease; SRD, serous retinal detachment; RPE, retinal pigment epithelium.
Figure 7 Color retinal photograph of the right eye showing swollen and hyperemic optic discs (A) and FFA showing hot disc (B) (white arrows), in the acute phase of vKHD.
Abbreviations: FFA, fundus fluorescein angiography; VKHD, Vogt–Koyanagi–Harada disease.
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fluorescence due to RPE migration.1,88 Complications such as 
CNV may also be seen on FFA (Figure 9).91
FFA is also found to have a prognostic value in acute 
VKHD, where the absence of early pinpoint peripapillary 
hyperfluorescence on pretreatment FFA is a poor prognostic 
factor for developing chronic VKHD, and its presence is 
observed in up to 85% of eyes that resolved.90
indocyanine green angiography
ICG is well established as a sensitive method to delineate the 
choroidal circulation and visualize the choroid.94 In VKHD, 
it is used to confirm the presence of choroidal inflammation, 
monitor choroidal activity and response to therapy.95,96 
However, it is an invasive and time-consuming imaging 
method, in which it is difficult to distinguish stromal scar-
ring rather than active choroiditis,97 and pretreatment ICG 
findings have been shown to have limited prognostic value 
for the development of chronic VKHD.90
The main ICG features in acute VKHD are: 1) a patchy 
hypofluorescence pattern at the posterior pole and retinal 
periphery during the early angiographic phase due to chor-
oidal inflammatory vasculopathy and delayed choroidal 
perfusion (Figure 10A); 2) large choroidal stromal vessel 
hyperfluorescence in the early phase (Figure 10B); 3) dif-
fusely leaking fuzzy choroidal vessels possibly due to vas-
culitis (Figure 10B); 4) hypofluorescent dark dots during the 
intermediate phase of angiography (Figure 10C), representing 
partial or full-thickness choroidal scaring and granulomas 
observed in all eyes in a series of 36 patients with acute 
VKHD.98 These dark spots are noted to regress with treatment 
at 2 months follow-up96 and even to completely resolve in 
some patients;95 5) diffuse choroidal hyperfluorescence in the 
late phase (22–28 minutes) (Figure 10D).96 Unlike in healthy 
eyes, where the optic disc remains hypofluorescent, VKHD 
eyes exhibit optic disc hyperfluorescence indicating severe 
papillitis and corresponding to the “hot disc” appearance on 
FFA, which resolves following treatment.95,98 Hypofluores-
cent patches in areas of exudative retinal detachments have 
been described during the early phases of the angiogram.98 
Choroidal folds are also seen in the late phase of the ICG as 
long hyperfluorescent lines radiating from the optic disc.91 
Patients with chronic VKHD usually display similar but less 
severe ICG findings to those seen in the acute phase, which 
Figure 8 FFA photograph of a patient in the acute phase of vKHD showing optic 
disc leakage and numerous hyperfluorescent pinpoint foci of leakage at the level of 
RPe leading to the classic “starry sky” appearance.
Abbreviations: FFA, fundus fluorescein angiography; VKHD, Vogt–Koyanagi–
Harada disease; RPe, retinal pigment epithelium.
Figure 9 Color retinal (A) and FFA (B) photographs of a vKHD patient with macular CNv (white arrows).
Abbreviations: FFA, fundus fluorescein angiography; VKHD, Vogt–Koyanagi–Harada disease; CNV, choroidal neovascularization.
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are fuzzy vessels, late diffuse choroidal hyperfluorescence, 
and hypofluorescent lesions corresponding to areas of cho-
rioretinal atrophy.99 Evidence of active ongoing choroidal 
inflammation can be detected even in the absence of manifest 
clinical inflammation. Signs of choroidal inflammation were 
found in ICG scans of 72.5% (31 of 51 eyes) of patients 
with chronic VKHD, regardless of their clinical appearance 
and duration of treatment, as clinically active disease was 
observed in only 41.2% (21 of 51 eyes) of those eyes.99
B-scan ultrasonography
Ultrasound (US) is a non-contact diagnostic imaging tech-
nique that uses high-frequency acoustic (sound) waves to 
provide a dynamic view of ocular structures. It has been 
found to be useful in diagnosing different stages of VKHD, 
particularly in cases with severe media opacities and a poor 
fundal view. Diffuse low-to-medium reflective choroidal 
thickening and SRD are evident during acute VKHD, espe-
cially when the SRD is too extensive.89 Swollen ciliary body 
with shallow anterior chamber, vitreous condensations, and 
scleral or episcleral thickening have also been seen on US 
in the acute stage.100–102 Subretinal fibrosis in chronic VKHD 
was described on US in 64.8% of the eyes with chronic 
VKHD as dome shaped, heterogeneous lesion; however, no 
other clinical signs of the chronic disease were detected on 
the US.103 Therefore, it is relatively unreliable in detecting 
subclinical recurrences and minor changes in choroidal thick-
ness due to its limited resolution in comparison to OCT.104
Fundus autofluorescence (FAF)
FAF is a noninvasive efficient imaging technique that provides 
valuable information on the RPE and outer retinal layers.105
Metabolic and functional activity of the RPE can be 
detected in different stages of VKHD using the short wave-
length light (blue) FAF that has been used to detect lipofuscin 
abnormalities and the near-infrared light FAF that has been 
used for melanin and melanin compound abnormalities.106 
Different patterns of FAF have been demonstrated in dif-
ferent phases of VKHD, which supports the role of the 
RPE in the disease and allows repeated close monitoring of 
Figure 10 iCG photographs of the right eye of a patient in the acute phase of vKHD showing (A) patchy hypofluorescence during the early angiographic phase, (B) large 
choroidal stromal vessel hyperfluorescence with fuzzy choroidal vessels in the early phase, (C) hypofluorescent dark dots during the intermediate phase of angiography, and 
(D) diffuse choroidal hyperfluorescence in the late phase.
Abbreviations: iCG, indocyanine green angiography; vKHD, vogt–Koyanagi–Harada disease.
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disease progression. In the acute phase, FAF demonstrates 
mild and uniform hyperautofluorescence in the macula 
and areas of hypoautofluorescence, corresponding to the 
areas of SRD.106,107 Resolution of the SRD with treatment 
after 1 month is associated with the appearance of placoid 
areas of hyperautofluorescence in the macula and peripapil-
lary regions. These FAF changes are more evident on the 
near-infrared FAF and typically resolve after 6 months 
of treatment.106 In the chronic phase of VKHD, areas of 
hypoautofluorescence (Figure 11A), hyperautofluorescence 
(Figure 11B), and lattice-like pattern in the peripheral fundus 
are observed.108 Areas of hypoautofluorescence on FAF cor-
responded with peripapillary atrophy and RPE loss, while 
increased autofluorescence matches areas of RPE prolifera-
tion on SD-OCT in chronic VKHD.109
Optical coherence tomography
Recent advances in OCT imaging allows visualization of 
the choroid and choriocapillaris by providing cross-sectional 
images of the choroid.110 It is a noninvasive method, which is 
used to measure choroidal thickness for frequent, quantitative 
assessment of disease activity and response to treatment in 
different phases of VKHD. The presence of SRDs is seen 
on OCT scans as areas of subretinal fluid.92,93 This is usu-
ally associated with formation of fibrinous subretinal septa 
dividing the subretinal space into several compartments.92 
Intraretinal edema, RPE undulation, choroidal folds, and 
choroidal hyperreflective dots can also be seen on the OCT 
scan in acute VKHD.67,111,112 Following resolution of the 
inflammation, with corticosteroid treatment, these signs 
resolve (Figure 12).113 Damage to the ellipsoid zone, per-
sistent choroidal folds, and RPE undulation have been cor-
related with poor visual prognosis.69,93,114 OCT can be used 
to differentiate VKHD from other similar conditions, such as 
CSCR. In a retrospective study that compared the SD-OCT 
Figure 11 Short wavelength light (blue) FAF photographs of eyes of a patient with chronic vKHD.
Notes: (A) Right eye showing areas of hypoautofluorescence (black arrow) corresponding to RPE atrophy and loss. (B) Left eye showing areas of hyperautofluorescence 
(white arrow) corresponding to RPe proliferation.
Abbreviations: FAF, fundus autofluorescence; VKHD, Vogt–Koyanagi–Harada disease; RPE, retinal pigment epithelium.
Figure 12 OCT scan of the macula of a patient in the acute phase of vKHD before 
and after starting corticosteroid treatment.
Notes: (A) SRD (white arrow) and a mild fluctuation in the ILM (red arrow). (B) 
Resolution of SRD with treatment (white arrow).
Abbreviations: OCT, optical coherence tomography; vKHD, vogt–Koyanagi–
Harada disease; SRD, serous retinal detachment; iLM, internal limiting membrane.
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features of acute VKHD and acute CSCR, SRD was found 
to be present in both diseases, while RPE folds, fluctuations 
(rising and falling) of the internal limiting membrane (ILM) 
and fibrinous subretinal septa were only present in VKHD 
(Figure 12). The CSCR cases were found to have signifi-
cantly more pigment epithelial detachments and bulges of 
the RPE.115 High-penetration OCT (HP-OCT) using a light 
source with a long wavelength (1,060 nm) may be superior 
to SD-OCT in visualizing structures beneath the RPE.116 
HP-OCT is used to study 42 eyes of 21 patients with acute 
VKHD, of whom 24 eyes of 13 patients (57.1%) developed 
choroidal folds at presentation.69 The presence of these folds 
significantly correlated with older age, presence of disc swell-
ing, increased choroidal thickness, and the development of 
sunset glow fundus at 6 months follow-up.69
Enhanced depth imaging (EDI)-OCT demonstrates that 
patients with the acute phase of VKHD have a marked increase 
in the average subfoveal choroidal thickness, possibly due 
to inflammatory infiltration and exudation, which reverses 
following systemic corticosteroid therapy and resolution of 
the inflammation.104,117 Choroidal thickness continues to be 
abnormally increased during the chronic recurrent phase.118 
An increase in choroidal thickness of .100 μm during 
corticosteroid tapering, even in the presence of apparently 
good clinical control, has been defined as rebound choroidal 
thickening suggesting recurrent subclinical inflammation.117 
While this can be accompanied by other ocular signs, such as 
anterior chamber cells and/or optic disc hyperfluorescence on 
FFA and/or dark dots on ICG,119 it can also precede them.47 
Rebound choroidal thickening on EDI-OCT was the only sign 
of ocular inflammation in a 71-year-old patient who presented 
6 months after his initial diagnosis with headache, tinnitus, 
and bilateral sensorineural hearing loss.120 Conversely, in 
chronic VKHD, sunglow fundus correlates with choroidal 
thinning on EDI-OCT scans.121 The mean subfoveal choroi-
dal thickness is significantly reduced in patients with severe 
depigmentation of the fundus, in comparison to patients with 
no-or-mild fundus depigmentation or healthy controls.122 
Subfoveal choroidal thinning and focal loss of the choriocap-
illaris, with preservation of medium (Sattler’s layer) and large 
choroidal vessels (Haller’s layer), have also been observed on 
SD-OCT scans of 26 eyes of 13 consecutive patients during 
the convalescent stage of the disease.80
Ancillary tests
electroretinography
Full-field electroretinography (ERG), which reflects the total 
electrophysiological activity of the entire retina, and the 
multifocal ERG, which represents the simultaneous electrical 
response of photoreceptors and the inner retina from differ-
ent regions, are used to evaluate visual function in patients 
with VKHD.123,124 Extensive chorioretinal atrophy in chronic 
VKHD is associated with abnormal ERG recordings, pos-
sibly due to inflammatory retinal changes. A marked diffuse 
reduction in the amplitude of both scotopic and photopic 
phases of full-field ERG is correlated with severe fundus 
depigmentation and fibrosis in those patients.123 Reduction 
in multifocal ERG is correlated with reduced vision before 
treatment in chronic VKHD and shows good recovery with 
immunosuppressive therapy, reflecting improvement in the 
visual function.124 Improvement in the N1 and P1 waves of 
multifocal ERG is observed after treatment in a prospective 
study that involved 22 eyes with VKHD, which suggests 
that ERG may be a useful tool to monitor peripheral retinal 
disease activity and response to treatment.125
Microperimetry
Microperimetry, which determines differential light sensi-
tivity at a certain retinal area, is used to assess the effect of 
VKHD on the retina and determine response to treatment. It 
provides a quantitative measurement of the visual function 
of a specific part of the retina and correlates that to OCT 
structural changes in that area. In patients with chronic 
VKHD, macular sensitivity on microperimetry and functional 
changes (best corrected visual acuity) match RPE thickening 
and other structural retinal changes on OCT scans. This could 
help in monitoring disease activity by assessing the visual 
function in those patients.126 Chronic recurrent disease with 
sunset glow fundus is associated with worse retinal sensitivity 
and poor visual outcome.127
Differential diagnosis of vKHD
The differential diagnosis of VKHD includes many other 
causes of panuveitis and posterior scleritis. Sympathetic 
ophthalmia (SO) has a similar clinical and histopathological 
appearance to VKHD, with swollen hyperemic optic discs and 
SRDs, and is in differential diagnosis of VKHD. However, 
bilateral granulomatous panuveitis in eyes with SO follow 
previous penetrating trauma or surgery to one eye.128,129
Posterior scleritis may present with SRD, optic disc swell-
ing and choroidal or retinal folds and may be a presenting 
feature of VKHD. However, in cases of posterior scleritis, pain 
is a common feature classically radiating to the forehead or face 
and waking the patient up during the night. In addition, poste-
rior scleritis is usually unilateral presenting often with reduced 
vision and ocular pain. Scleral and choroidal thickening, fluid 
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in the Tenon’s capsule, and optic nerve head with the resulting 
“T sign” appearance are characteristic features on US.70,71,83
CSCR is an idiopathic condition that commonly affects 
healthy middle-aged men and is characterized by the devel-
opment of SRDs, and patients may present with headaches 
that might be mistaken for the prodromal stage of VKHD. 
However, in CSCR, visual acuity remains good, patients 
do not complain of ocular pain and there is no evidence 
of granulomatous ocular inflammation or a hot optic disc 
on FFA.51,130 Infectious choroiditis caused by syphilis,131 
tuberculosis,132 and Bartonella henselae infection133,134 should 
also been considered in the differential diagnosis of VKHD. 
Cat scratch disease caused by B. henselae can present with 
headache, tinnitus, panuveitis, optic disc swelling, and dif-
fuse choroidal thickening mimicking VKHD. However, in 
cat scratch disease, the CSF is usually normal with raised 
antibody titers against B. henselae in the serum.134
Other less frequent causes of panuveitis include intraocu-
lar lymphoma that can present with neurological features and/
or panuveitis masquerade appearance with thickened choroid 
and multifocal yellowish subretinal lesions.135 The rare occur-
rence of idiopathic uveal effusion syndrome is another dif-
ferential that presents with scleral thickening, subacute onset 
of exudative detachments of choroid and retina but with no 
intraocular inflammation.136 Finally, ocular sarcoidosis can 
present as a granulomatous anterior uveitis or panuveitis with 
choroidal and optic disc granulomas, segmental phlebitis, 
and SRDs.137 Pulmonary findings, as well as elevated serum 
angiotensin-converting enzyme levels, will help differentiate 
the two conditions.
Treatment
The goal of treatment in VKHD is to suppress active ocular 
inflammation, prevent disease relapse and avoid sight-
threatening complications. As such, early diagnosis and rapid 
commencement of treatment are important in preserving 
vision in these young patients. Multiple therapeutic regimens 
are used combining both systemic immunosuppression agents 
together with locally administered corticosteroids and anti-
vascular endothelial growth factor drugs (anti-VEGF).138–142 
Because VKHD can involve multiple organs, the mainstay 
of treatment is based on high-dose systemic corticosteroids,43 
administered either orally or intravenously.143 Oral predni-
sone at a dose of 1–2 mg/kg/day started early in the course of 
the disease followed by slow tapering to avoid recurrences is 
the generally accepted regimen,144,145 while pulse intravenous 
corticosteroid therapy of 1 g/day of methylprednisolone for 
3–5 days followed by oral prednisolone is usually reserved 
for cases with severe inflammation.43 Slow tapering of the 
corticosteroid dose, with frequent follow-up examinations, is 
warranted in order to avoid recurrence of posterior segment 
inflammation.144 Aiming to reach a dose of ,7.5 mg/day 
over several months and keeping patients on long-term treat-
ment may reduce the risk of relapses, but nonetheless, these 
occur even when inflammatory control is achieved at high 
doses.27,44 Treatment at these low, safe doses with no evident 
ocular inflammation should be maintained for several years 
before cessation of therapy is considered. Topical corticos-
teroids and cycloplegic agents are effective in controlling 
the anterior segment inflammation.34 The addition of second-
line immunosuppressive agents including mycophenolate 
mofetil, methotrexate, cyclosporine, or azathioprine are 
usually considered in patients who are not controlled with 
corticosteroids alone or cannot be tapered to a safe low dose 
for the extended period of time they require to control their 
inflammation.146–148 Use of these agents has been found to 
shorten the duration of the acute stage and to reduce the 
risk of progression to the chronic stages and development of 
sight-threatening complications.138,149,150 Their addition early 
in the disease has been found to be associated with a better 
visual outcome in comparison to corticosteroids alone or if 
their addition is delayed.138,151
While intravitreal and posterior subtenon triamcinolone 
acetonide injections have been found to be effective in 
short-term control of inflammation during the acute phase 
of VKHD,139,140 intravenous infusion of anti-tumor necrosis 
factor α agents (adalimumab and infliximab) and rituximab, 
which is an anti-CD20 monoclonal antibody, has been used in 
refractory cases and found to be effective in long-term disease 
control.152–154
Intravitreal injections of anti-VEGF have been used suc-
cessfully for the treatment of CNVs,155 and combined treat-
ment of triamcinolone acetate and anti-VEGF has also been 
tried to treat recurrent CNVs.156 Persistent SRDs involving 
the fovea in four patients with bilateral VKHD were success-
fully resolved using intravitreal injections of anti-VEGF.142
Complications associated with VKHD
Although the inflammation can be controlled by corticoster-
oids and other immunosuppressive agents, some patients may 
still have a poor visual outcome due to development of other 
sight-threatening complications such as glaucoma, cataract 
(which can be treated), CNV, and subretinal fibrosis (Table 1). 
These complications tend to occur during the chronic stage of 
the disease and are associated with a poor visual outcome,1,2 
especially if there is delayed presentation.86
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Glaucoma is the most common complication of VKHD 
with an incidence of up to 45%.157–159 Secondary glaucoma 
has been attributed to a combination of ciliary body 
inflammation, pupillary block, formation of anterior syn-
echiae leading to trabecular meshwork obstruction and 
uveal effusion.159,160 In one study, glaucoma occurred in up 
to 38% of VKHD patients with the majority requiring surgi-
cal intervention to control their IOP.159 A lower incidence of 
15.8% has been reported by another group, in whom IOP was 
controlled mainly by medical treatment. The authors propose 
that aggressive use of steroid-sparing immunosuppressive 
agents to control the inflammatory process in their cohort, 
as well as the effectiveness of the currently available topical 
anti-glaucoma medication, prevented the need for glaucoma 
surgery.160
Cataract is the second most common complication of 
VKHD,157,158,161 with an incidence of up to 42%.2,34 Prolonged 
steroid treatment and recurrent ocular inflammation are the 
main risk factors for its development.1,30 Cataract surgery is 
usually recommended only when the inflammation is qui-
escent for at least 3 months and should be performed with 
preoperative steroid cover for up to 2 weeks.162,163 Other 
less common complications that might be responsible for 
visual loss in patients with VKHD include peripapillary 
and macular CNVs,164 which develop in up to 14.7%,165 and 
subretinal fibrosis.2,30,34 Subretinal fibrosis can occur in up 
to 40% of VKHD patients165 and may lead to substantial 
visual impairment when the fovea is involved.166 Unlike 
other ocular inflammatory conditions, CME appears to be a 
relatively rare complication of VKHD.160,167 Other uncom-
mon complications (Table 1) includes posterior synechiae,158 
rhegmatogenous retinal detachment and ERM160 and MH 
formation,84 band keratopathy,168 and pseudotumoral RPE 
proliferation.169,170 The high number of complications together 
with delayed treatment and poor visual acuity at presentation 
especially in older patients is found to be associated with 
poor prognosis.2,171
Conclusion
VKHD is a multisystemic autoimmune disease affecting 
mainly middle-aged patients; it has four distinct phases 
that may not present in sequential order and detection of 
subclinical inflammation is still a challenge. Therefore, 
in order to avoid delayed treatment and development of 
sight-threatening complications that tend to occur mostly 
in patients with long-standing ocular inflammation, it is 
important to recognize the variable clinical presentations 
of the disease. Utilizing ocular imaging for diagnosis 
and repeat use of noninvasive modalities, such as OCT 
to monitor disease activity, can promote early treatment 
and prevent the development of ocular complications. 
Early aggressive treatment with systemic corticosteroids 
during the acute stage is highly recommended. The use 
of immunosuppressive agents has reduced the risk of 
developing ocular complications; however, a considerable 
number of patients still progress to the chronic stages, suf-
fer recurrences and progress to visual loss, probably due 
to undetectable and undertreated subclinical inflamma-
tion. Further prospective studies using sensitive imaging 
methods are needed to help clarify the role of ongoing 
choroidal inflammation and RPE activity on the clinical 
course of the disease and its effect on retinal function and 
visual outcome.
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